参考文献：

［1］Sarin S K,KUMAR A.Noncirrhotic portal hypertension［J］. Clin Liver Dis,2006,10:627-651.

［2］NAYAK N C,RAMALINGASWAMI B. Obliterative portal venopathy of the liver［J］.Arch Pathol Med 1969,87:359-369.

［3］OKUDARIA M,OHBU M,OKUDA K. Idiopathic portal hypertension and its pathology［J］. Semin Liver Dis,2002,22:59-71.

［4］NAKANUMA Y,TSUNEYAMA K. OHBO M,KATAYANAGI K.Pathology and pathogenesis of idiopathic portal hypertension with an emphasis on the liver［J］. Pathol Res Pract 2001,197:65-76.

［5］RAJESH S,MUKUND A,SUREKA B,et al.Non－cirrhotic portal hypertension: An imaging review［J］.Abdom Radiol （NY）,2018,43（8）: 1991-2010.

［6］SARIN S K,KUMAR A,CHAWLA Y K,et al.Noncirrhotic portal fibrosis/idiopathic portal hypertension:APASL recommendations for diagnosis and treatment［J］.J Hepatol Int 2007;1:398-413.

［7］SHERMAN M S,SAMORE W R,PRATT D S.Myelofibrosis and portal hypertension:the case for primary variceal screening［J］. ACGCase Rep J,2020,7（2）:333.(https://www.daowen.com)

［8］CHATTOPADHYAY S,NONDY S. Portal biliopathy［J］. World J Gastroenterol,2012,18（43）:6177-6182.

［9］VERSTOVSEK S,MESA R A,GOTLIB J,et al.A double-blind, placebocontrolled trial of ruxolitinib for myelofibrosis［J］.N Eng J Med,2012,366（9）:799-807.

［10］HARRISON C,KILADJIAN J J,AL-ALI H K,et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis［J］. N Eng J Med,2012,366（9）:787-798.

［11］中华医学会血液学分会白血病淋巴瘤学组.原发性骨髓纤维化诊断与治疗中国指南（2019 年版）［J］.中华血液学杂志，2019，40（1）：1-7.

［12］PHILLIP V, BERGER H, STRAUB M, et al. Transjugular intrahepatic portosystemic stent-shunt for therapy of bleeding esophageal varices due to extramedullary hematopoiesis in primary myelofibrosis:a case report［J］.Onkologie,2012,35（6）:368-371.

（陈梦容　林勇　林春　潘晨）